Signal Genetics (Licensor)NeoGenomics (Licensee)
Signal Genetics granted NeoGenomics' NeoGenomics Laboratories subsidiary rights to offer Signal's Myeloma Prognostic Risk Signature (MyPRS) gene expression profile test in the U.S.
Array BioPharma (Other)Signal Genetics (Other)
Array will use Signal Genetics' MyPRS genomic testing technology to select patients for two upcoming clinical trials of ARRY-520
Set Email Alert